Mate, I don't think it's good advice to ring the company when all the info is on their website. First thing in business is to know your product so if you haven't researched your product which to me means that you haven't searched the competing companies to differentiate what makes ADMEDUS the gold standard and the short answer to that is the science.
So unless you know the science and the global market meaning knowing who the players are and what percentage of the market they own you have got Buckley's chance of getting the truth out of a company selling the product making claims that their product has all these qualities but once compared to the real gold standard there are no comparisons. (ADAPT)
I absolutely agree with the valuation of ADMEDUS depending on their products being the gold standard. The past management hadn't marketed the products correctly hence the NEW marketing. And with a start-up with no track record, I find it hard for a major cardiology hospital to just change direction with no track record. And 3 reps out of 12 said a lot about the last management compared to now.
$300M market cap = $1.20 and I agree with you.
But don't blame a worker e.g: the fish stinks from the head down to the tail.
You don't have to forgive the old, but this is the new don't mix the two.
AHZ Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)